Latest news and press releases about RenovoRx, Inc. (RNXT): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
RenovoRx, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing therapies for solid tumor malignancies. The company's primary investigational therapy, RenovoGem, is an innovative drug and device combination. It integrates intra-arterial gemcitabine with the RenovoCath system, currently progressing through pivotal Phase III clinical trials for the treatment of locally advanced pancreatic cancer. Established in 2009, RenovoRx, Inc.
Price
| Price | $1.55 |
| Market Cap | $70M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 8.16 |
| EV / EBITDA | -8.01 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -145.63% |
| Return on Invested Capital | -139.74% |
| Return on Assets | -107.09% |
| Gross Margin | 84.41% |
| Operating Margin | -678.04% |
| Net Margin | -621.71% |
Related companies: ANVS · BCAB · CALC · CELU · ELUT · LTRN · MAIA
Explore sector: Healthcare · Biotechnology
More sections of RNXT: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks